Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 2Hemangiosarcoma 2Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Neurofibrosarcoma 1Neoplasms 1Malignant mesenchymal tumor 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiopericytoma, Malignant 1Gliosarcoma 1Glioblastoma 1Fibrosarcoma 1Dermatofibrosarcoma 1Chondrosarcoma, Extraskeletal Myxoid 1Brain Neoplasms 1

Interventions

Temozolomide 131Radiotherapy 87Bevacizumab 43Radiation 31Carmustine 29Magnetic Resonance Spectroscopy 22Irinotecan 22Erlotinib Hydrochloride 22Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Watchful Waiting × Sarcoma × Clear all
NCT01122888 2015-04-28

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1 Terminated
41 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡